Atossa logo
 
Jan 06, 2021
Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market

Dec 17, 2020
Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market

Dec 08, 2020
Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering

Nov 13, 2020
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Nov 10, 2020
Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

Oct 19, 2020
Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

Oct 07, 2020
Registration Is Now Open For Atossa Therapeutics' Tribe Public Webinar Presentation and Q&A Event On October 13, 2020

Sep 21, 2020
Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020

Sep 17, 2020
Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

Sep 01, 2020
Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19

   1    2   3   4   5   6 

Privacy